Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar
Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar
复制标题
DOI：
10.1016/s0035-9203(97)90288-1
复制
发表时间：
1997-07-01
影响因子：
2.2
通讯作者：
White, NJ
中科院分区：
文献类型：
--
作者：
Smithuis, FM;Monti, F;White, NJ
在缅甸西部边境的若开邦，氯喹 (CQ) 和乙胺嘧啶/磺胺多辛 (PS) 是该地区目前治疗单纯性恶性疟原虫疟疾的治疗方法，这项公开比较研究对 289 名患者进行了评估，前瞻性地分为 3 个年龄组。氯喹治疗与更快的临床康复相关（P=0.03），但总体治愈率比 PS 治疗差； 72% (102/141) 接受 CQ 治疗的病例未能在 14 天内清除寄生虫血症或复发，而接受 PS 治疗的病例则为 47% (69/148)（P
In Rakhine States on the western border of Myanmar, the efficacy of chloroquine (CQ) and pyrimethamine/sulfadoxine (PS), the current treatments for uncomplicated Plasmodium falciparum malaria in this area, was evaluated in an open comparative study of 289 patients, stratified prospectively into 3 age groups. Chloroquine treatment was associated with more rapid clinical recovery (P=0.03), but the overall cure rates were worse than for PS treatment; failure to clear parasitaemia or recrudescence within 14 d occurred in 72% (102/141) of cases treated with CQ compared to 47% (69/148) of those who received PS (P